D64.3 Other sideroblastic anemias
The ICD-10-CM code for Other sideroblastic anemias is D64.3 (FY2026). It is a billable, claim-ready diagnosis code.
Classification
- Section
- D60-D64: Aplastic and other anemias and other bone marrow failure syndromes (D60-D64)
- Category D64
- 10 codes (8 billable)
- FY2026 Status
- Stable since FY2024
Also Known As
ICD-10-CM Alphabetic Index entries that lead to D64.3:
- Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) › pyridoxine-responsive
- Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) › sideroblastic
- Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) › hypochromic (idiopathic) (microcytic) (normoblastic) › pyridoxine-responsive
- Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) › sideroblastic › specified type NEC
- Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) › sideroblastic › pyridoxine-responsive NEC
- Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) › vitamin › B6-responsive
Inclusion Terms
- Sideroblastic anemia NOS
- Pyridoxine-responsive sideroblastic anemia NEC
U.S. Hospital Utilization
- An estimated 240 U.S. inpatient stays in 2023 included D64.3 among the documented diagnoses.
Source: National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, 2016–2023. National survey-weighted estimates.
Official Coding Guidelines
Chapter 3 TOC entry3. Chapter 3: Disease of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89) ............................................................................................. 39
Reserved for future guideline expansionReserved for future guideline expansion ...................................................................................... 39
Source: CMS — ICD-10-CM Official Guidelines for Coding and Reporting, FY2026